Join us this Thursday, 2/27, for an exciting look at the next generation of blood-based predictive biomarkers for therapy selection.

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Get in touch